MichaelBoyiadzisMD
Oncology • Pittsburgh, PAAssistant Professor, Medicine, University of Pittsburgh School of Medicine
Are you Dr. Boyiadzis?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 46 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 Meyran Ave
Suite 318
Pittsburgh, PA 15213Phone+1 412-586-9874Fax+1 412-647-4486
Summary
- Dr. Michael Boyiadzis, MD is an oncologist in Pittsburgh, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania and Maryland. He is affiliated with UPMC Presbyterian Shadyside, UPMC Magee-Womens Hospital, and Shadyside Campus.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2001 - 2005
St Agnes HealthCareResidency, Internal Medicine, 1998 - 2001
University of Debrecen Medical and Health Science CenterClass of 1995
Certifications & Licensure
PA State Medical License 2004 - 2024
MD State Medical License 2001 - 2006
Clinical Trials
- Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia Start of enrollment: 2008 Sep 01
- QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia Start of enrollment: 2014 May 12
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
- Join now to see all
Publications & Presentations
PubMed
- 153 citationsSignificance and implications of FDA approval of pembrolizumab for biomarker-defined disease.Michael Boyiadzis, John M. Kirkwood, John L. Marshall, Colin C. Pritchard, Nilofer S. Azad
Journal for Immunotherapy of Cancer. 2018-05-14 - 8 citationsDesign of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia.Vladimir Ivanov, Su-Peng Yeh, Jiri Mayer, Lalit Saini, Ali Unal
Future Oncology. 2022-08-01 - 340 citationsBlast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-...Miroslaw J. Szczepanski, Marta Szajnik, Ann Welsh, Theresa L. Whiteside, Michael Boyiadzis
Haematologica. 2011-09-01
Press Mentions
- DPP4+ Exosomes in AML Patients’ Plasma Suppress Proliferation of Hematopoietic Progenitor CellsNovember 2nd, 2020
